Arbutus Biopharma Corporation $ABUS is Foursixthree Capital LP’s 9th Largest Position

Foursixthree Capital LP reduced its holdings in shares of Arbutus Biopharma Corporation (NASDAQ:ABUS) by 22.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,978,975 shares of the biopharmaceutical company’s stock after selling 578,392 shares during the quarter. Arbutus Biopharma makes up about 2.5% of Foursixthree Capital LP’s holdings, making the stock its 9th largest position. Foursixthree Capital LP’s holdings in Arbutus Biopharma were worth $8,985,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bank of America Corp DE grew its stake in Arbutus Biopharma by 21.1% in the 3rd quarter. Bank of America Corp DE now owns 1,450,822 shares of the biopharmaceutical company’s stock valued at $6,587,000 after purchasing an additional 253,167 shares during the period. Alliancebernstein L.P. raised its stake in shares of Arbutus Biopharma by 19.7% during the 3rd quarter. Alliancebernstein L.P. now owns 143,870 shares of the biopharmaceutical company’s stock worth $653,000 after purchasing an additional 23,630 shares during the period. Man Group plc boosted its holdings in shares of Arbutus Biopharma by 103.5% in the 3rd quarter. Man Group plc now owns 79,374 shares of the biopharmaceutical company’s stock worth $360,000 after buying an additional 40,377 shares during the last quarter. ADAR1 Capital Management LLC boosted its holdings in shares of Arbutus Biopharma by 2.7% in the 3rd quarter. ADAR1 Capital Management LLC now owns 2,903,226 shares of the biopharmaceutical company’s stock worth $13,181,000 after buying an additional 77,453 shares during the last quarter. Finally, Brooklyn Investment Group grew its position in Arbutus Biopharma by 3,485.6% during the third quarter. Brooklyn Investment Group now owns 14,163 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 13,768 shares during the period. Hedge funds and other institutional investors own 43.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Arbutus Biopharma in a report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Arbutus Biopharma presently has a consensus rating of “Hold” and a consensus target price of $5.00.

Arbutus Biopharma Stock Performance

Shares of ABUS opened at $4.26 on Monday. Arbutus Biopharma Corporation has a fifty-two week low of $2.70 and a fifty-two week high of $5.10. The business has a 50-day moving average of $4.35 and a 200 day moving average of $4.41. The firm has a market cap of $819.28 million, a P/E ratio of -18.52 and a beta of 0.69.

About Arbutus Biopharma

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company dedicated to discovering, developing and advancing a cure for chronic hepatitis B virus (HBV) infection. The company’s pipeline features both direct-acting antivirals and host-targeting therapies designed to reduce viral load and restore immune function. Lead programs include an RNA interference (RNAi) candidate aimed at silencing viral gene expression and next-generation capsid assembly modulators that seek to inhibit viral replication at its core.

In addition to its antiviral portfolio, Arbutus leverages proprietary lipid nanoparticle (LNP) delivery technology to optimize the distribution and cellular uptake of nucleic acid therapeutics.